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Introduction: Congenital heart defect (CHD) with shunt can lead to severe, even irreversible
pulmonary arterial hypertension (PAH); in extreme form to Eisenmenger syndrome (ES). Despite
relatively good long-term survival, these patients often suffer from cyanosis and multisystemic
dysfunction, where pulmonary artery thrombosis can be a potentially fatal complication.
Together with bleeding these are the most frequent causes of non-cardiac death in patients
with severe PAH due to CHD.
Patients and methods: Prospective study of 40 patients with severe PAH due to CHD (28 female/12
male, median age 41.5 years) was performed, with the aim to analyze the presence of pulmonary
artery thrombosis and correlating anatomical and laboratory risk factors.
Results: Previous thrombosis and/or thromboembolic event was found in 7 patients (17.5%).
Signiﬁcant differences in cyanotic vs non-cyanotic patients were in red blood count parameters:
median hemoglobin level 195 vs 141 (po0.0001), median erythrocytes count 6.62 vs 4.881012/l
(po0.0001), median hematocrit 0.58 vs 0.44 (po0.0001). Laboratory ﬁndings causing increased risk
for thrombosis were increased thrombocytes aggregation in 15 patients (37.5%), hypercoagulation in
5 patients (12.5%) and endothelial dysfunction in 8 patients (20%). Anatomical risk factor—severe
pulmonary artery dilatation (440 mm in female and 445 mm in male) was found in 19 patients
(51.4%).
Conclusions: Patients with severe PAH due to CHD represent a high-risk group for pulmonary artery
thrombosis with morphological and ﬂow pathology combined with secondary erythrocytosis and
coagulation abnormalities. A relatively high incidence of platelet hyperaggregability shown in our
study would propose that aspirin therapy might be considered in some highly selected patients with
severe PAH due to CHD. Further studies though are needed to support this data.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All rights
reserved.
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The presence of a hemodynamically signiﬁcant congenital heart
defect (CHD) with shunt can lead to increased pulmonary arterial
ﬂow and pressure. The onset and severity of pulmonary arterial
hypertension (PAH) are quite variable according to the type of
CHD, and in an extreme form can lead to Eisenmenger syndrome
(ES) with irreversible PAH [1,2], contraindicated to any further
correction.
Pulmonary arterial chances in PAH are closely studied but still
not completely understood. Endothelial dysfunction and histo-
morphological changes in small pulmonary arterial vessels are the
releasing factors of PAH [1]. Due to the increased pulmonary
arterial pressure and resistance a secondary dilatation of proximal
pulmonary artery is seen, with in situ thrombosis also described
[1]. Even pulmonary artery dissection or rupture is sometimes
reported [3,4].
ES represents a unique group among patients with PAH. The
long-term survival of these patients is traditionally described as
much better compared to those with other types of severe PAH
[1,2,5]; despite the presence of extreme pulmonary arterial
pressure, which can be systemic or even suprasystemic. This is
usually contributed to the well preserved right ventricular (RV)
function [5–8]. The presence of the defect is supposed to serve as
a “pop-off valve”, enabling the severely overloaded RV decom-
pression and so preventing its decompensation and failure. This is
why patients with a late CHD closure usually do much worse than
before surgery or compared to patients with persistent cardiac
shunting.
On the other hand, this RV “protection” in ES is paid with the
cost of right-to-left shunting through the defect that leads to
mixing of desaturated blood to systemic circulation resulting in
patient's cyanosis. Cyanosis and systemic hypoxemia lead again to
compensatory secondary erythrocytosis, changes in hemocoagu-
lation and also changes in most of the body organs [5,9,10].
So, in ES, patients have complications resulting not only from
the CHD and PAH but also from cyanosis and multisystemic
dysfunction [9,10]. Therefore there are combined several risk
factors for possible pulmonary arterial thrombosis (Fig. 1).ig. 1 – Complex pathological situations than can lead to pulmo
isenmenger syndrome.On the other hand these patients often suffer from severe
bleeding complications as well. Both these complications are the
most common cause of “non-cardiac” death in ES, as frequently as
in 20% [11].
The necessity or the appropriateness of anticoagulation ther-
apy is often discussed and until now it is not solved. In patients
with PAH it is usually recommended [1] but in ES subgroup of
patients the use of anticoagulation is a controversy [2,11–14], with
no real beneﬁt proven; also in the guidelines there is no expert
consensus on this point. On the contrary, often secondary fatal
bleeding complications with or without anticoagulation therapy
are described.2. Aims of the study
The aim of the study was to analyze patients with severe PAH due
to CHD for the presence of pulmonary artery thrombosis and risk
factors, like pulmonary arterial dilatation, and establishing possi-
ble correlations with cyanosis, secondary erythrocytosis and
coagulation abnomalities. The aim was to deﬁne high-risk
patients where anticoagulation therapy would be most proﬁtable.3. Patients
The patients analyzed were 40 patients with severe PAH due to
CHD, 28 female (70%) and 12 male (30%), with median age 41.5
years (23–78 years). Age groups were as follows: there were 16
patients with ≤40 years of age (40%), 17 patients between 40 and
60 years (42.5%) and 7 patients ≥60 years (17.5%).
23 patients (57.5%) had a simple shunt lesion (atrial septal
defect, ventricular septal defect or persistent arterial duct) and
7 patients (17.5%) had a combined shunt and 10 patients (25%)
a complex heart defect. Nine (22.5%) patients had a previous
defect closure without a residual shunt. All patients had an
invasively conﬁrmed severe PAH (mean pulmonary artery pres-
sure 445 mmHg; and systolic pulmonary pressure 42/3 of
systemic systolic arterial pressure).nary artery thrombosis and/or bleeding in patients with
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to previously present major bleeding event; 9 patients (22.5%)
were on full anticoagulation (desired INR 2–2.5) therapy due to
other risk factors (like atrial ﬁbrillation and/or previously
reported thromboembolic event; and the other 23 patients
(57.5%) were on low-dose anticoagulation (desired INR 1.8–2.0).4. Methods
Patients were evaluated prospectively and partially retrospec-
tively. Medical history, clinical status, laboratory and echocardio-
graphic ﬁndings were evaluated in all patients; computer
tomography (CT) or magnetic resonance imaging (MRI) was
performed and analyzed in 23 patients (in some it was impossible
due to their mental disability (Down syndrome), or due to their
refusal or other technical problems).
Medical history was obtained from his/her health card and
during the personal interview. Objective clinical status was
evaluated, dominantly for signs of cyanosis and clubbing.
Routine laboratory evaluation of blood count and capillary
oxygen saturation was performed. At specialized hematology
laboratory a detailed analysis of hemocoagulation parameters,
thrombocytes count, thrombocytes aggregation assessment and
endothelial dysfunction evaluation was performed [15,16]. Plate-
let aggregation was investigated by light transmission aggrego-
metry without stimulation (i.e. spontaneous aggregation), and
after induction by arachidonic acid 0.5 mg/mL, adenosine dipho-
sphate (ADP) 20 mmol/l, collagen 10 μmol/L, epinephrine
300 μmol/L and ristocetin 1.0 μmol/L, as well as after three
concentrations of low-dose platelet inducers ADP (2 mmol/L,
1 mmol/L, and 0.5 mmol/L) and epinephrine (10 mmol/L, 1 mmol/L,
and 0.5 mmol/L). All blood collections were carried out between
08:00 and 09:00 AM after an overnight fasting with minimal
trauma from antecubital vein. The samples were treated imme-
diately, at least up to 2 h after blood collection. Plasma von
Willebrand factor (vWF) and plasminogen activator inhibitor type
1 (PAI-1) were used as indicators of endothelial dysfunction and/
or damage. Plasma for blood coagulation and endothelial para-
meters were immediately separated by centrifugation and ana-
lyzed, or frozen at −80 1C until tested.
Echocardiography was performed with Philips iE33 ultrasound
system or GE Vivid 7, both with digital archive system. The studies
were obtained from standard projections; measurements of the
main pulmonary artery (MPA) were taken from the parasternal
short axis view; it was measured 3 times and the mean value was
taken. CT or MRI measurements of the main pulmonary artery
were performed and the presence/absence of pulmonary artery
thromboembolic ﬁnding was analyzed.Table 1 – Thromboembolic events in our patients.
Anamnestic clinical event
 Pulmonary artery thrombo/embolism
 Ischemic/embolic central nervous event
 Deep venous thrombosis
 Intracardiac (right atrial) thrombus4.1. Statistical analysis
Continuous data are presented as median and range; nominal
data as percentage. Statistical analysis was performed using
Windows Microsoft Excel 2007 and software package JMP 5.0.1
(SAS Institute, Inc., Cary, NC). Univariate analysis was performed
to analyze correlation between parameters. In case of continuous
data T-test and non-parametric Wilcoxon test were used, and in
case of nominal data contingence tables were used. A p value less
than 0.05 was considered signiﬁcant.5. Results
Anamnestic ﬁnding of previous pulmonary thromboembolic
event (PTE), deep venous thrombosis or embolism (systemic—
central nervous or other) was found in 7 patients (17.5%)—Table 1.
In 7 patients (17.5%) lower extremities varicosity was found.
Clinically apparent cyanosis with clubbing and also laboratory
ﬁnding of systemic hypoxemia (O2 saturationo90%) were present
in 24 patients (60%).
The presence of PTE was signiﬁcantly more frequently occurring in
older patients (59 vs 40 years, p¼0.0093), where all PTEs were
present after 40 years of age. PTEs were more frequent in female
21.4% vs 8.3% in male, though this was not statistically signiﬁcant.
Type of the congenital heart defect or the presence of cyanosis did not
show a statistically signiﬁcant correlation with the presence of PTE.
Blood count showed increased red count levels: median
hemoglobin (Hb) in male was 181 g/l (141–218), in female
169 g/l (118–230), and median erythrocyte (Ery) count in male
was 6.01012/l (5–8.2), in female 5.61012/l (4.1–8.9), with 21
patients (52.2%) with severely increased red blood count. Median
hematocrit (Htc) in male was 0.55 (0.44–0.66) and in female 0.51
(0.37–0.73), with only 3 patients (7.5%) who had the hematocrit
above 0.65. On the other hand only in one of these patients (2.5%)
a clinically marked hyperviscosity syndrome was present. There
was a signiﬁcant difference in cyanotic vs non-cyanotic patients in
red count parameters (Fig. 2): median Hb 195 g/l (145–230) vs
141 g/l (118–173) (po0.0001), median Ery 6.621012/l (5.19–8.9)
vs 4.881012/l (4.1–5.95) (po0.0001), median HTc 0.58 (0.45–
0.73) vs 0.44 (0.37–0.52) (po0.0001).
Detailed hemocoagulation analysis showed increased risk for
thrombosis (Fig. 3): (1) increased thrombocytes aggregation in 15
patients (37.5%), (2) hypercoagulation in 5 patients (12.5%) and (3)
endothelial dysfunction in 8 patients (20%). At least one of these
pathologies was present in 23 patients (57.5%), two combined
pathologies in 4 patients (10%), and all three hemocoagulation
abnormalities were found in 1 patient (2.5%). No correlation of
laboratory increased risk of thrombosis and cyanosis or increased
red blood count was found.No of pts. (%)
3 pts. (7.5%)
3 pts. (7.5%)
3 pts. (7.5%)
1 pt. (2.5%)
Fig. 3 – Presence of pathological laboratory findings (pts—
patients).
Fig. 4 – Echocardiographic and CT findings of severe central
pulmonary artery dilatation (MPA—main pulmonary artery).
Fig. 2 – Laboratory findings—comparison of hemoglobin, erythrocytes and hematocrit in cyanotic vs non-cyanotic patients
(Hb—hemoglobin, Ery—erythrocytes, and HTc—hematocrit).
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found in all patients and the dilatation was progressive with age
(p¼0.04). Severe MPA dilatation (440mm in female and 445mm
in male) (Fig. 4) was found in 19 patients (51.4%). While in patients
o40 years of age only 26.7% patients had severe AP dilatation, in the
age group 40–60 years it was 66.7% and 460 years it was 71.4% of
patients (p¼0.04). Sex or type of the congenital heart defect or the
presence of cyanosis did not correlate with MPA dilatation. CT or MRI
signs of pulmonary thromboembolism were present in 3 patients
(7.5%); previously known distal type embolus were present in 2
female patients (5%) and newly found asymptomatic proximal
embolus in 1 male patient (2.5%) (Fig. 5).
When analyzing the risk factors for pulmonary thrombosis
(MPA dilatation and hemocoagulation abnormalities)—at least
one of these factors were found in 31 patients (77.5%), and both
of these risk factors were present in 11 patients (27.5%). There was
no correlation found between hemocoagulation abnormalities
and/or MPA dilatation and the clinical presence of PTEs.Fig. 5 – MRI finding of central pulmonary artery embolus in
patient with Eisenmenger syndrome.6. Discussion
The pathological and pathophysiological mechanisms leading to
pulmonary artery thrombosis in severe PAH and Eisenmenger
syndrome constitute a very complex problem, where more issues
have to be taken into account, complicated even more by the fact
that they may be combined together quite variably. Isolated red component of the blood count showed typical
increase in cyanotic compared to non-cyanotic patients.
This was proving compensatory erythrocytosis that enables
them best possible oxygen delivery in a general hypoxemic
status. This fact has to be taken into account when dealing
with a cyanotic patient. It seems to be an evident matter but
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especially in some types of CHDs (like in persistent arterial
duct where cyanosis is found only in the lower half of the
body, or in atrial septal defects where clinical manifestation of
desaturation sometimes occurs only after physical activity); or
simply because a less experienced doctor is involved, so the
cyanosis is missed and/or oxygen saturation is not established.
So, while dealing with these patients, one always has to know
what is the “normal”, i.e. the usual hemoglobin level of such a
patient, so as not to miss a serious, especially rapid fall in its
level, for this may mean for a cyanotic patient a life-
threatening situation (i.e. due to bleeding). Laboratory pro-thrombotic ﬁndings may be represented by acti-
vated coagulation factors, increased thrombocytes aggregation
and also by endothelial dysfunction (which is a risk factor for
both arterial and venous thrombosis). At least one of these
abnormalities was present in more than half of our patients
(51.4%), but combined abnormalities were found too (Fig. 3),
increasing the potential risk for thrombosis even more.
Despite the presence of various hemocoagulation pathology
(hypercoagulation and/or increased thrombocytes aggregation
and/or endothelial dysfunction) in our patients there was no
correlation with cyanosis and/or increased red cell blood count;
and also no correlation with clinical manifestation of thrombosis
was found.
On the other hand these patients tend also to thrombocytopenia
and/or thrombocytes dysfunction which may contribute to oppo-
site types of problems as well- to more or less severe bleeding
complications. This was also found in our patients though not
included and presented in this study. It is therefore very important
to be very careful when and how to propose anticoagulation
therapy in these patients.
There was a surprisingly high incidence of increased thrombocytes
aggregation found in our patients (37.5%) which is usually not
described in literature and would need a further detailed hema-
tological study. But when pathological thrombocytes aggregation
is present, and especially when it is isolated (which was up to 30%
in our group) without any other clinical or laboratory pathology, it
would then perhaps rationalize aspirin therapy instead of the use
of warfarin. Though, no such proposal can be found in the
literature so far. And, on the other hand, of course, aspirin might
again cause an increased risk of bleeding complications, so these
therapeutic considerations have to be evaluated very carefully. Severe (even aneurysmatic) pulmonary artery dilatation repre-
sents a serious ﬁnding in patients with severe PAH, appears to be
very frequent (in more than 50% of patients) and is progressive
with age, as shown in our study. This dilatation is the result of the
patient's hemodynamic situation (severe pulmonary pressure and
ﬂow overload). Other factors like pulmonary arterial wall mor-
phological and functional changes and pathological blood ﬂow
patterns as well as coagulation abnormalities most probably also
play an important role. They are surely contributing to the
increased risk of pulmonary artery thrombosis, but there is still
very little information on the topic.A relatively low incidence of clinically manifest thromboem-
bolic events (especially newly developed) in our patients may be
due to the use for anticoagulation strategy at our center(especially in patients with other indications for anticoagulation,
like atrial ﬁbrillation). On the other hand, of course, some silent
pulmonary thromboembolic ﬁndings might have been missed out
in our study, as we were not able to perform CT and/or MRI in all
patients, despite the fact that the central part of the pulmonary
arteries was also well scanned by echocardiography and no
thromboemoli were detected.
Despite the fact that we could not prove a signiﬁcant correla-
tion between the occurrence of clinical thromboembolic event
and MPA dilatation or hemocoagulation abnormalities, we still
consider these patients as a very high-risk group, especially when
the above mentioned factors are combined. In the presence of
pulmonary artery aneurysm (especially when giant) anticoagula-
tion therapy may be perhaps indicated. On the other hand, it is
extremely important to take into consideration any clinical
presence of bleeding, especially hemoptysis or any laboratory
pathology consistent with the increased risk of bleeding compli-
cations, as these may be life threatening for the patient. So it is
neccessary to be strictly individual.7. Conclusions
Patients with severe PAH due to CHD, and especially Eisenmenger
syndrome, represent a very high-risk group of patients for
pulmonary artery thrombosis. These patients suffer from histo-
morphological and functional pathology of distal small arterioles
combined with severe proximal vessel dilatation due to patholo-
gical hemodynamic situation with extreme ﬂow and pressure
overload, even more often combined with secondary erythrocy-
tosis and coagulation changes. On the other hand, these patients
very often tend to have major bleeding episodes as well. Both of
these complications (thrombosis and bleeding) may be fatal for
them. The question of anticoagulation therapy is therefore still
open and has to be considered strictly individually, also taking
into account all other accessory clinical ﬁndings (i.e. atrial
ﬁbrillation with the need of higher anticoagulation level or on
the contrary, the presence of bleeding events where any treat-
ment might be too risky). A special topic may represent a
surprisingly high incidence of platelet hyperaggregability, as
shown in our study. Especially when found without any other
clinical or laboratory pathology it would perhaps propose that
aspirin therapy could be considered in some higly selected
patients with PAH and CHD. Further data though are needed to
support this theory.
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